Emerging Therapeutics in the U.S. Non-small Cell Lung Cancer Markets : Market Research Report

1. U.S. Total Market Overview for NSCLC
        1. Executive Summary
                1. Executive Summary
        2. Research Scope and Segmentation
                1. Scope and Segmentation
                2. Research Methodology
        3. Disease Overview
                1. Introduction
                2. Etiology
                3. Diagnosis and Staging
                4. Treatment Overview
        4. Patient Forecast
                1. Patient Incidence Forecast
                2. Patients per Line of Therapy
                3. Patient Forecast of Untreated Patients
        5. Line of Therapy Revenue Forecasts
                1. Market Engineering Measurements
                2. Revenue Forecasts for First Line Therapy
                3. Revenue Forecasts for Second Line Therapy
                4. Revenue Forecasts for Third Line Therapy and Unmet Need Population
        6. General Market Trends
                1. Industry Challenges
                a. Failure to Gain First Line Therapy Approval Hinders Total Market Revenue
                b. Targeted Therapies are not Making as Great an Impact as Once
                    Predicted Slows Market Penetration
                c. Poor Five-year Survival for Late Stage NSCLC Confines Treatment Duration
                d. Difficulty Finding Optimal Combination of Drugs Prevents
                    Accelerated Revenue Growth
                e. Difficulty in Identifying Correct Patient Population Slows Entry to Market
                2. Market Drivers
                a. Large Population Entices More Companies to Enter Market
                b. Large Population with Unmet Needs Promotes Access to New Patient Populations
                c. Ease of Use and Better Safety Profile Lead to Increased Market Share
                d. Scientific Interest Increases Attention to NSCLC Market
                e. FDA Approval Facilitates Easier Entry to Market
                3. Market Restraints
                a. Short Survival Time of Late Stage NSCLC Truncates Market Size
                b. Late Diagnosis Curtails Ability to Effectively Treat Patients
                c. Changes in Medicare Law Hinder Oncologists' Prescription Habits
                d. Generic Impact Restricts Market Revenue
                4. Oncologists' Perspectives on Current and Future NSCLC Therapies
        7. Frost & Sullivan Awards
                1. Customer Service Leadership Award
                2. Company of the Year Award
                3. Technology Innovation Award
                4. Product of the Year Award
                5. Business Development Strategy Leadership Award

2. U.S. Cytotoxic Markets for NSCLC
        1. Overview
                1. Introduction
                2. Market Engineering Measurements
        2. Forecasts and Trends
                1. Treatment Protocols and Cost per Cycle
                2. Revenue Forecasts
        3. Competitive Analysis
                1. Competitive Structure
                2. Market Share Analysis
                3. Product Analysis
                4. Pipeline Analysis

3. U.S. Targeted Therapies Markets for NSCLC
        1. Overview
                1. Introduction
                2. Market Engineering Measurements
                3. Treatment Protocols and Cost of Therapy
                4. Revenue Forecasts for Targeted Therapies
        2. EGF Pathway
                1. Mechanism of Action
                2. Product Analysis
                3. Pipeline Analysis
                4. Revenue Forecasts
        3. Angiogenesis
                1. Mechanism of Action
                2. Pipeline Analysis
                3. Revenue Forecasts
        4. Cell Proliferation/Apoptosis Pathway
                1. Mechanism of Action
                2. Pipeline Analysis
                3. Revenue Forecast
        5. Immune Response Pathway
                1. Mechanism of Action
                2. Pipeline Analysis
                3. Revenue Forecasts
        6. Competitive Analysis
                1. Competitive Structure
                2. Market Share Analysis

4. Appendix
        1. Decision Support Database
                1. Physicians
                2. Total Male Population
                3. Total Female Population
                4. Prevalence of Male Smokers
                5. Prevalence of Female Smokers
                6. Population of Age 65 or Older

Abstract

Once touted as the next big thing in curing cancer, targeted therapies have fallen drastically short of the expectations of the healthcare community regarding the ability to treat non-small cell lung cancer (NSCLC). In fact, targeted therapies such as Iressa and Tarceva have failed to gain approval as first line therapies for NSCLC and are instead preferred as second- and third-line treatment options. Although targeted therapies have not shown the results required to replace chemotherapy completely in NSCLC patients, there is hope among oncologists that these are likely to be successful as adjuvant treatments post-surgery or in combination with chemotherapy. However, in the long run, targeted therapies seeking to achieve blockbuster status need to move from their position as second- or third-line therapies towards standard of care treatment for NSCLC.

This Frost & Sullivan research evaluates the key developments in the NSCLC therapeutics market and analyzes the key drivers and challenges affecting current and future growth. It also provides in-depth pipeline and product analysis for cytotoxic and targeted therapies.

Absence of Chemotherapy in NSCLC Treatment Presents Opportunities for Targeted Therapies

While chemotherapy is the treatment of choice for first and second line NSCLC, targeted therapies are expected to make an impact on patients too sick for chemotherapy or unwilling to take chemotherapy. "Late stage NSCLC patients that are unlikely to derive the full benefits of chemotherapy might also consider targeted therapies to improve their quality of life if not extend it," says the analyst.

There could be various other grounds on which a patient might be forced to skip or voluntarily refuse chemotherapy. For instance, patients over the age of 70 or with poor health may be advised against the chemotherapy treatment. Other patients might refuse treatment since the intense side effects outweigh the clinical benefits of chemotherapy. Annually, approximately 20,000 patients do not receive chemotherapy and, though this is a relatively small population, it is still a large enough group to create significant revenue increase for other treatment options.

Equipped with Added Advantages, Targeted Therapies Compete with Chemotherapy

Although chemotherapy reigns supreme as the first line of treatment for NSCLC, targeted therapies are not far behind with their ability to offer easier administration (in the form of pills and injections) and a lower side-effect profile compared to chemotherapy agents. Armed with such benefits, if targeted therapies succeed in gaining approval as a first line of treatment for NSCLC, it can access a population size of 60,000 to 70,000 patients. "Combined with the high cost of targeted therapies, such a large population size is expected to drive this market forward," explains the analyst.

Emerging Therapeutics in the U.S. Non-small Cell Lung Cancer Markets

Table of Contents

Abstract